Literature DB >> 1626630

Motor symptoms of the Rett syndrome: abnormal muscle tone, posture, locomotion and stereotyped movement.

Y Nomura1, M Segawa.   

Abstract

Amongst the motor, mental, cognitive and emotional symptoms of the Rett syndrome (RS) the motor symptoms stand out as the hallmark in analyzing the essential pathophysiology. Summarizing the motor symptoms and searching into the knowledge of relevant basic sciences, this report aims at stressing the pathophysiological basis of RS which we have reported in previous studies. The core motor symptoms of RS consist of two aspects; firstly the unique developmental abnormalities of the discrepancy of crawling and walking and secondly the pathognomonic symptoms which include the abnormal muscle tone, posture, locomotion and stereotyped movement. The deranged crawling reflects the abnormal locomotive function. The primary responsible neuronal structures of the abnormal muscle tone, posture and locomotion are probably in the brainstem. Aberrantly formed neuronal structures responsible for voluntary movements and modulatory factors from the basal ganglia are the pathophysiological basis of the stereotyped movement of RS. Thus the neuronal structures that underlie the clinical characteristics of RS extend broadly from the motor neurons to the higher cortex, but involve the specific neuronal systems. The most important and primary of these specific neuronal systems are thought to be the monoaminergic systems, originating from the brainstem and midbrain. Abnormally deficient noradrenergic, serotonergic and dopaminergic systems result in the abnormal modulation of ontogeny and function of the higher and lower nervous systems. As we have already stressed, this unique putative pathophysiological basis could explain the very striking set of clinical symptoms of RS and their age dependent appearance despite the lack of major specific findings in neuropathology.

Entities:  

Mesh:

Year:  1992        PMID: 1626630

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  8 in total

Review 1.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

2.  Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome.

Authors:  Lianne Robinson; Jacky Guy; Leanne McKay; Emma Brockett; Rosemary C Spike; Jim Selfridge; Dina De Sousa; Cara Merusi; Gernot Riedel; Adrian Bird; Stuart R Cobb
Journal:  Brain       Date:  2012-04-23       Impact factor: 13.501

3.  Rett Syndrome.

Authors:  E E J Smeets; K Pelc; B Dan
Journal:  Mol Syndromol       Date:  2012-04-16

4.  Quantification of functional abilities in Rett syndrome: a comparison between stages III and IV.

Authors:  Carlos Bm Monteiro; Geert Jp Savelsbergh; Ana Rp Smorenburg; Zodja Graciani; Camila Torriani-Pasin; Luiz Carlos de Abreu; Vitor E Valenti; Fernando Kok
Journal:  Neuropsychiatr Dis Treat       Date:  2014-07-03       Impact factor: 2.570

5.  Anaplerotic triheptanoin diet enhances mitochondrial substrate use to remodel the metabolome and improve lifespan, motor function, and sociability in MeCP2-null mice.

Authors:  Min Jung Park; Susan Aja; Qun Li; Alicia L Degano; Judith Penati; Justin Zhuo; Charles R Roe; Gabriele V Ronnett
Journal:  PLoS One       Date:  2014-10-09       Impact factor: 3.240

6.  The Quality of Life in Girls with Rett Syndrome.

Authors:  Lucia Parisi; Teresa Di Filippo; Michele Roccella
Journal:  Ment Illn       Date:  2016-05-18

7.  MeCP2 deficiency results in robust Rett-like behavioural and motor deficits in male and female rats.

Authors:  Kelsey C Patterson; Virginia E Hawkins; Kara M Arps; Daniel K Mulkey; Michelle L Olsen
Journal:  Hum Mol Genet       Date:  2016-06-21       Impact factor: 6.150

8.  Gait analysis in a Mecp2 knockout mouse model of Rett syndrome reveals early-onset and progressive motor deficits.

Authors:  Kamal K E Gadalla; Paul D Ross; John S Riddell; Mark E S Bailey; Stuart R Cobb
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.